safety signal
Lilly’s triple agonist retatrutide posts strongest weight-loss data to date, with unusual sensory skin side effect reported
Eli Lilly; retatrutide; triple agonist; triple hormone receptor agonist; GLP-1; GIP; glucagon; obesity; weight loss; TRIUMPH-4; Phase III; dysesthesia; abnormal sense of touch; safety signal; side effects
FDA Places Clinical Hold on Five Gilead HIV Studies Due to Safety Concerns
FDA; Gilead Sciences; HIV; clinical hold; GS-1720; GS-4182; clinical trials; safety signal; CD4+ T-cell; lymphocyte count; Biktarvy; lenacapavir